Detalles de la búsqueda
1.
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies.
J Allergy Clin Immunol;
151(1): 172-181, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36195170
2.
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Lancet;
397(10290): 2151-2168, 2021 06 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34023008
3.
Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial.
Clin Infect Dis;
70(4): 549-556, 2020 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30918967
4.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
Clin Infect Dis;
71(8): 1920-1929, 2020 11 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31905383
5.
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Lancet;
393(10167): 143-155, 2019 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30420123
6.
Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286.
J Infect Dis;
211(5): 780-90, 2015 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25214516
7.
Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.
J Infect Dis;
210(8): 1248-59, 2014 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24795473
8.
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⺠T-cell recovery despite sustained virologic suppression: ACTG A5256.
J Infect Dis;
206(4): 534-42, 2012 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22740718
9.
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1.
Infect Dis Ther;
12(9): 2321-2335, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37751019
10.
Growth analysis among adolescents with moderate-to-severe atopic dermatitis receiving upadacitinib in combination with topical corticosteroids in Japan: A case study series from a phase 3, randomized, controlled trial (Rising Up).
World Allergy Organ J;
15(9): 100678, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36185549
11.
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.
JAMA Dermatol;
158(4): 404-413, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35262646
12.
Potent HIV-specific responses are enriched in a unique subset of CD8+ T cells that coexpresses CD4 on its surface.
Blood;
114(18): 3841-53, 2009 Oct 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-19700667
13.
IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.
Blood;
113(25): 6304-14, 2009 Jun 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-19380868
14.
To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment.
AIDS;
35(8): 1201-1208, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33710017
15.
Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
J Acquir Immune Defic Syndr;
87(2): 794-800, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33587500
16.
The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients.
HIV Clin Trials;
11(6): 351-8, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-21239363
17.
Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine.
Clin Pharmacol Drug Dev;
9(2): 189-202, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31724343
18.
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
J Acquir Immune Defic Syndr;
84(1): 60-65, 2020 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31977595
19.
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
J Acquir Immune Defic Syndr;
83(3): 310-318, 2020 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31834000
20.
The effect of aging on T-regulatory cell frequency in HIV infection.
Clin Immunol;
130(3): 298-303, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19008157